… the new immunotherapeutics for COVID-19 disease. … and immunotherapeutic strategies in
patients with COVID-19. The most likely mechanism of the immunopathogenesis of COVID-19 …

… progression and death in hospitalised patients with COVID-19. Among anti-cytokine … , we
focused on the baseline characteristics of the patients recruited, identifying the most favourable …

… conducting interventional trials in patients with COVID-19, we need to remember the lessons
learned from the ongoing sepsis epidemic that kills 250 000 people annually in the USA. …

… Most of the therapeutic options that are available for managing COVID-19 are based on
previous experiences in treating SARS- and MERS-CoV. A major reason for the lack of …

… find an immediate medication option to resist the SARS-CoV-2 infection in patients. A French
… Serological analyses show that IgA & IgM antibodies appear in COVID-19 patients within 5 …

… IVIg therapy is another immunotherapeutic option for managing COVID-19 patients besides
other options [Citation89,Citation90]. The efficacy of IVIg therapy can be further enhanced by …

… Regarding the evaluation of live coronavirus in research and clinical settings, it is necessary
that all laboratory operations should be handled with care under bioassay level 3 conditions …

… most profound in patients who progress to severe Covid-19. Recent studies … patients with
different degrees of disease severity. These studies have attributed the severe form of Covid-19 …

… choosing optimal immunotherapy for patients with severe … and discuss promising
immunotherapies for COVID-19, including … promising treatment option for COVID-19 patients, …

… Coronavirus disease 2019 (COVID-19) infection which is caused by severe acute respiratory
syndrome coronavirus… are major components of COVID-19 pathogenesis. The former …